Drug intelligence / Profile preview

NCX 1047

Development stage: Preclinical
Lead developer: NicOx
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Topical, Systemic

Overview

NCX 1047 is a nitric oxide (NO)-donating anti-inflammatory drug developed primarily for dermatological indications, including seborrhea and other skin and musculoskeletal diseases. The compound was initially developed by Nicox in collaboration with Grupo Ferrer. Preclinical studies have shown encouraging results, suggesting a differentiated product profile compared to existing therapies. As of the latest available updates, clinical development has not advanced beyond preclinical or early-stage planning due to delays in initiating clinical trials[1][3][5][8][10].

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on NCX 1047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCX 1047.

Explore the full profile